  Finally, while past testing methods allowed identification of chromosomal abnormalities such as Trisomy 13, Trisomy 18, Trisomy 21 (Down Syndrome), and monogenic disorders such as Huntington’s disease, next generation sequencing (NGS) technologies now permit an unparalleled wealth of information about fetuses’ and embryos’ genomes.  Although these technologies are not yet used routinely, their utility is being assessed in clinical trials. Should this expanded genomic information be available on prenatal testing panels? Or for all prospective parents who request prenatal testing? What about other additions that might be of interest to particular parents, even if the genetic linkages to the particular traits are less direct or even only mildly predictive: diabetes, obesity, or psychiatric conditions such as bipolar disorder or schizophrenia?